GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Level Biotechnology 3118.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

30.30

0.00%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Level Biotechnology

Its shares trade on Taipei Exchange under the ticker 3118.TWO. It has been listed since 10 September 2004. In the fiscal year to 31 December 2025, it reported revenue of TWD 736.6m and net income of TWD 79.7m. At that date it held total assets of TWD 866.8m and shareholders' equity of TWD 580.2m.

Level Biotechnology, Inc. engages in the provision of biotechnological services. The company is headquartered in Taipei, New Taipei. The company went IPO on 2004-09-10. The firm's main products include cell culture series, immune protein series, gene nucleic acid and molecular biology series and instrument series. The firm also provides preclinical testing services, such as genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing and biocompatibility testing. The firm distributes its products in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Providers & Services
Listed since
10 Sept 2004

Leadership

Pay as last reported

  • Chunlong QiuChairman of the Board, General Manager, since 1993
  • Yixian LiFinance Manager, Corporate Governance Officer
  • Yiqun QiuDeputy General Manager-Instrument Business, Director, since 1996
  • Jinyuan LinDirector
  • Lifeng ShaoDirector
  • Xiting WangDirector
  • Yongfeng ZhangDirector
  • Mr. Yanhui KeIndependent Director
  • Mr. Ting-Yang LiuIndependent Director
  • Yongsen LiuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • The company provides diverse biotechnological services and products.
  • Main products include cell culture and immune protein series.
  • Preclinical testing services cover genetic and general toxicology.

Weaknesses

  • Products are distributed only in the domestic market.
  • The company operates in a single city location.
  • Reliance on a limited geographic distribution area.

Opportunities

  • Expanding distribution to international markets is possible.
  • Growing demand for preclinical testing services exists.
  • New product lines can diversify revenue streams.

Threats

  • Competitors may offer broader distribution networks.
  • Regulatory changes could impact testing services.
  • Economic shifts might affect domestic market demand.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.